BenevolentAI Investor Presentation Deck
We expect BEN-2293 to provide both symptomatic relief
and to reverse disease progression in atopic dermatitis
• BEN-2293 is highly selective for Trk receptors, with IC50
potencies in the low nM range for TrkA, B, and C
• BEN-2293 dose dependently inhibits release of inflammatory Th1
and Th2 cytokines TNFa, IFNY, IL-13, and IL-4 in human peripheral
blood mononuclear cells (PBMCs) stimulated with an inflammatory
T-cell stimulus (anti-CD3/CD28)
• BEN-2293 inhibits the release of Calcitonin Gene-Related
Peptide (CGRP), a mediator of itch, sensory nerve
hypersensitisation and neurogenic inflammation, in dorsal root
ganglion (DRG) isolated from adult rats and stimulated with NGF
• BEN-2293 series significantly (p<0.05) reduced mouse ear
inflammation following administration of PMA, significantly
reducing expression of cytokines IL-1B, IL-4, IL-6, CXCL1, MCP-1, and
Tarc
• BEN-2293 demonstrates excellent tolerability and safety margins
in IND/CTA-enabling toxicology studies
Key: Tropomyosin-related kinase (Trk) receptor tyrosine kinase family, namely TrkA, TrkB, and TrkC;
Nerve Growth Factor (NGF); Brain Derived Neurotrophic Factor (BDNF); Neurotrophin-3 (NTF-3)/NT3
BEN-2293 Inhibition of human primary T-cell activation
Luminescence
% Inhibition
25000
20000-
15000-
10000-
5000-
0.1
100-
75-
50-
25-
0-
-25-
-50-
TNFa
Inhibition of sensory
neuron activation
-3
-2
THE M
1000 10000
TIME TIITE
10 100
BEN-2293 nM
10 100 1000 10000
BEN-2293 nM
Human PBMCs from 2 donors. Anti-CD3/CD28 stimulus +/- BEN-2293
Hillslope
IC50
-1
0
Log BEN-2293 (μm)
- Donor 1
Donor 2
2.827
0.03033
1
1500
Net ear thickness (x 0.01 mm)
1000-
500-
15-
0.1
IL-4
Sham-
Reduction in mouse ear
inflammation
H..
Vehicle
Crisabarole (Img)-
Tacrolimus (0.05mg)
-Donor 1
Donor 2
PanTrk (0.5mg)-
Dexamethasone (0.1mg)-
Benevolent 41View entire presentation